MedTrace Logo

Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors

NCT00572078 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 27

Last updated 2017-09-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability and describe the maximum tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.

Conditions

Interventions

DRUG

Sorafenib

Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Bayer

    collaborator INDUSTRY

  • Safi Shahda

    lead OTHER

Principal Investigators

  • Safi G Shahda, MD · Indiana University School of Medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-23
Primary Completion
2011-01-04
Completion
2014-09-14

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00572078 on ClinicalTrials.gov